Physiotherapy assessment and treatment for an ambulant child with cerebral palsy after Botox A to the lower limbs: A case report

Pediatric Physical Therapy

Volumn 18, Issue 1, 2006, Pages 39-48

  Mulligan, Hilda ^a   Wilmshurst, Erin ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b NZCCS Canterbury   (New Zealand)

Author keywords

Botox; Case report; Cerebral palsy; Child; Physical therapy methods

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; CASE REPORT; CEREBRAL PALSY; CHILD; CLINICAL FEATURE; EVALUATION; FUNCTIONAL ASSESSMENT; GAIT; GASTROCNEMIUS MUSCLE; GOAL ATTAINMENT SCALE; HAMSTRING; HUMAN; MALE; MOTOR PERFORMANCE; MUSCLE FUNCTION; PASSIVE MOVEMENT; PHYSIOTHERAPY; RATING SCALE; SPASTICITY; THERAPY EFFECT; TREATMENT OUTCOME;

BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD, PRESCHOOL; HUMANS; LOWER EXTREMITY; MUSCLE SPASTICITY; MUSCLE, SKELETAL; NEUROMUSCULAR AGENTS; PHYSICAL EXAMINATION; PHYSICAL THERAPY MODALITIES; RANGE OF MOTION, ARTICULAR; TREATMENT OUTCOME;

EID: 33748138205     PISSN: 08985669     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pep.0000202252.92562.4c     Document Type: Article

References (28)

1. Ade-Hall RA, Moore AP. Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy. The Cochrane Library 2004;1.
2. Mulligan H, Borkin H, Chaplin K, et al. The efficacy of botulinum toxin A in the treatment of spasticity in ambulant children with cerebral palsy - a structured review. N Z J Physiother. 2001;29:18-28.
3. Corry IS, Cosgrove AP, Duffy CM, et al. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomized prospective trial. J Pediatr Orthop. 1998;18:304-311.
4. Galli M, Crivellini M, Santambrogio GC, et al. Short-term effects of "botulinum toxin a" as treatment for children with cerebral palsy: kinematic and kinetic aspects at the ankle joint. Funct Neurol. 2001;16:317-323.
5. Koman LA, Mooney 3rd, JF Smith BP, et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop. 2000;20:108-115.
6. Paolicelli PB, Ferrari A, Lodesani M, et al. Use of botulinum toxin type A in walking disorders of children with cerebral palsy. Eur Medicophys. 2001;37:83-92.
7. Ubhi T, Bhakta BB, Ives HL, et al. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child. 2000;83:481-487.
8. Wong V. Use of botulinum toxin injection in 17 children with spastic cerebral palsy. Pediatr Neurol. 1998;18:124-131.
9. Wong V. Evidence-based approach of the use of botulinum toxin type A (BTX) in cerebral palsy. Pediatr Rehabil. 2003;6:85-96.
10. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997;6:S146-S168.
11. Ubhi T, Bhakta BB, Ives HL, et al. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child. 2000;83:481-487.
12. Dumas HM, O'Neil ME, Fragala MA. Expert consensus on physical therapist intervention after botulinum toxin A injection for children with cerebral palsy. Pediatr Phys Ther. 2001;13:122-132.
13. O'Neil ME, Fragala MA, Dumas HM. Physical therapy intervention for children with cerebral palsy who receive botulinum toxin A injections. Pediatr Phys Ther. 2003;15:204-215.
14. Russell DJ, Rosenbaum PL, Cadman DT, et al. The gross motor function measure: A means to evaluate the effects of physical therapy. Dev Med Child Neurol. 1989;31:341-352.
15. Bjornson KF, Graubert CS, Buford VL, et al. Validity of the gross motor function measure. Pediatr Phys Ther. 1998;10:43-47.
16. Palisano RJ, Haley SM, Brown DA. Goal attainment scaling as a measure of change in infants with motor delays. Phys Ther. 1992;72:432-437.
17. Boyd RN, Graham HK. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol. 1999;6(suppl 4):S23-S35.
18. Fragala MA, O'Neil ME, Russo KJ, et al. Impairment, disability, and satisfaction outcomes after lower-extremity botulinum toxin A injections for children with cerebral palsy. Pediatr Phys Ther. 2002;14:132-144.
19. Koman LA, Mooney 3rd, JF Smith BP, et al. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop. 1994;14:299-303.
20. Mackey AH, Lobb GL, Walt SE, et al. Reliability and validity of the Observational Gait Scale in children with spastic diplegia. Dev Med Child Neurol. 2003;45:4-11.
21. Graham HK, Aoki KR, Autti-Ramo I, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture. 2000;11:67-79.
22. Palisano R, Rosenbaum P, Walter S, et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39:214-223.
23. Russell D, Rosenbaum P, Gowland C, et al. Gross Motor Function Measure Manual, 2nd ed. Hamilton, Ontario, Canada: McMaster University; 1993.
24. Stuberg WA, Fuchs RH, Miedaner JA. Reliability of goniometric measurements of children with cerebral palsy. Dev Med Child Neurol. 1988;30:657-666.
25. Olney SJ, Wright MJ. Cerebral palsy. In: Campbell SK, ed. Physical Therapy for Children. Philadelphia: WB Saunders;1995:489-523.
26. Goldstein M, Harper DC. Management of cerebral palsy: Equinus gait. Dev Med Child Neurol. 2001;43:563-569.
27. Podsiadlo D, Richardson S. The timed "up & go": A test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39:142-148.
28. Sadaria KS, Bohannon RW. The 6-minute walk test: A brief review of literature. Clin Exerc Physiol. 2001;3:127-132.